Huadong Medicine's Fully-Owned Subsidiary's Collaborative Project Receives Full FDA Approval for ELAHERE® (Mirvetuximab Soravtansine) in Platinum-Resistant Ovarian Cancer

36Kr learned that Huadong Medicine Co., Ltd. announced recently that its wholly-owned subsidiary, Huadong Medicine Co., Ltd., and its U.S. partner AbbVie, announced that ELAHERE® (mirvetuximab soravtansine injection), an ADC drug for the treatment of platinum-resistant ovarian cancer, has received full approval from the U.S. Food and Drug Administration (FDA).Original Link